<DOC>
	<DOC>NCT01509196</DOC>
	<brief_summary>The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HIP0901 capsules and Lipidilsupra tablets.</brief_summary>
	<brief_title>A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet</brief_title>
	<detailed_description />
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy male volunteers, age between 20 and 45 Informed of the investigational nature of this study and voluntarily agree to participate in this study Weight＞50kg, BMI of ＞18kg/m2 and ＜27kg/m2 subject Acute disease within 28 days prior to start of study drug administration Use of any prescription medication within 14 days prior to Day 1 Use of any medication within 7 days prior to Day 1 Has a severe medical history of hypersensitivity to fibric acid derivative Participation in another clinical study within 30 days prior to start of study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Fenofibric acid</keyword>
	<keyword>HIP0901</keyword>
	<keyword>Lipidilsupra</keyword>
</DOC>